StockNews.AI
RAPP
StockNews.AI
90 days

Rapport Therapeutics to Host 2025 Investor and Analyst Day

1. RAPP will host its inaugural Investor Day on June 2, 2025. 2. Focus on RAP-219 Phase 2a trial in refractory focal epilepsy. 3. Dr. Jacqueline A. French will participate as a keynote speaker. 4. The event aims to attract investor interest in RAPP's clinical programs. 5. RAP-219 is a leading candidate targeting neurological disorders.

4m saved
Insight
Article

FAQ

Why Bullish?

Investor engagement and updates on RAP-219 can boost confidence and demand. Successful events often lead to positive stock movements, especially in clinical-stage biotechs.

How important is it?

The event has significant visibility with potential to influence investor perceptions significantly. Direct updates on a lead drug offer a compelling catalyst for stock movement.

Why Short Term?

Investor sentiment may shift quickly post-event, impacting stock price. Historical cases show similar events often drive near-term investor interest.

Related Companies

NYSE: ALNYNasdaq: FGENNasdaq: PTGX
BOSTON and SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced it will host its inaugural Investor and Analyst Day on Monday, June 2, 2025, in New York City. The event will also be webcast live. Rapport senior management will review the company’s clinical programs, with a focus on the RAP-219 Phase 2a trial in refractory focal epilepsy. The event will also feature a fireside chat with Dr. Jacqueline A. French—a globally recognized leader in epilepsy research, professor of Neurology at NYU Langone's Comprehensive Epilepsy Center, founder and director of the Epilepsy Study Consortium, and principal investigator of the RAP-219 Phase 2a trial. Event Details:Date: Monday, June 2, 2025Time: 3:00 – 5:00 p.m. Eastern TimeLocation: Nasdaq MarketSite, New York City Live and archived webcasts of the presentation can be accessed by visiting ‘Events & Presentations’ in the Investors section on the Company's website at https://investors.rapportrx.com. About Rapport TherapeuticsRapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological or psychiatric disorders. The Company’s founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport’s RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently pursuing RAP-219 as a potential treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders. ContactJulie DiCarloHead of Communications & IR, Rapport Therapeuticsjdicarlo@rapportrx.com

Related News